Dr. Hunter Champion answers the question: 'What Is A Biventricular Pacemaker?' — -- Question: What is a biventricular pacemaker or cardiac resynchronization therapy (also called a CRT device), ...

Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable ...

Amsterdam, Netherlands – 26 Aug 2023: Upgrade to cardiac resynchronisation therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodelling ...

AMSTERDAM -- A cardiac resynchronization therapy (CRT) upgrade produced solid clinical benefit for patients with pacing-induced heart failure with reduced ejection fraction (HFrEF), the small BUDAPEST ...

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced approval from the U.S. Food and Drug Administration (FDA) for the Allure Quadra ™ ...

CHICAGO, Nov 14 (Reuters) - Patients with mild to moderate heart failure benefited from an implanted Medtronic Inc device that combines a pacemaker to coordinate pumping with a defibrillator that ...

Please provide your email address to receive an email when new articles are posted on . Medtronic recalled ICDs and CRT-Ds with a glassed feedthrough made after Oct. 13, 2017 due to risk for low- or ...

New York, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "EU5 Cardiac Rhythm Management Procedures Outlook to 2025 - Pacemaker Implant Procedures, Cardiac ...

Please provide your email address to receive an email when new articles are posted on . Among patients with nonischemic cardiomyopathy, women were less likely to die or have a ventricular event than ...

Tom Derrington, 65, was increasingly having trouble walking up the four flights of stairs on the CapMetro construction site where he works. He was out of breath. His feet were so swollen they hurt on ...

SAN DIEGO, CA—The observational BIO-LIBRA study, which enrolled nearly 50% women, has revealed important outcome differences by both sex and device type among patients with nonischemic cardiomyopathy ...